Mankind Pharma Acquires Rivotril Brand From Roche For India

Strategic Acquisition
On March 18, 2026, Mankind Pharma confirmed the deal with Roche, marking a significant expansion in its central nervous system (CNS) therapies. The acquisition adds a clinically established brand with strong specialist recall, positioning Mankind to leverage Rivotril’s legacy in India’s growing neuropsychiatric market.

Market Impact
Rivotril is a well-recognized brand in the treatment of epilepsy, anxiety disorders, and other neurological conditions. By acquiring exclusive rights, Mankind Pharma aims to enhance accessibility and expand its footprint in chronic therapies. The move also aligns with the company’s strategy to diversify beyond acute care into long-term treatment segments.

Key Highlights

• Mankind Pharma acquires Rivotril brand from Roche for India
• Exclusive rights to manufacture, market, and distribute secured
• Rivotril is the innovator brand of clonazepam, widely used in CNS therapies
• Acquisition strengthens Mankind’s chronic therapy and neuro portfolio
• Deal positions Mankind for future line extensions in CNS treatments

Outlook For Pharma Sector
Industry experts view this acquisition as a pivotal step for Mankind Pharma in consolidating its presence in high-growth therapeutic areas. With increasing demand for neurological and psychiatric treatments in India, the company is expected to benefit from both brand recognition and expanded market share.

Sources: InvestyWise, Business Upturn